Imagine a high-tech GPS for cancer treatment that tells doctors exactly who will respond to a specific drug before they start. Instead of guessing, this system uses special MRI scans to see if cancer cells are actually 'hungry' and growing. At the same time, it fixes the supply chain for the radioactive ingredients needed for the treatment, making sure hospitals don't run out.
Lu-177-PSMA therapy is effective but suffers from supply chain instability and a 30% non-response rate in patients, leading to wasted expensive isotopes and unnecessary patient side effects.
A Clinical Investigational Device for Metabolic MRI, a 1.5T MRI scaling method using CEST, and an industrial process for Lu-177 production and Ytterbium recycling.
If you are an isotope manufacturer dealing with supply shortages and waste—this project developed a recycling process for Ytterbium and increased Lu-177 production capacity. This ensures a more robust supply chain and increases EU autonomy.
If you are an MRI provider dealing with the limited reach of high-field 7T systems—this project developed CEST technology to bring metabolic imaging to widely available 1.5T MRI systems. This allows more clinics to offer advanced triage tools.
If you are a clinic dealing with the fact that 30% of patients do not benefit from Lu-177-PSMA but still suffer side effects—this project developed MeMRI biomarkers to better stratify patients. This reduces wasted doses and improves patient outcomes.
Based on available project data, specific pricing or cost details for the MeMRI tools are not provided.
Yes, the project specifically focuses on scaling MeMRI technology for 1.5T MRI platforms and increasing the manufacturing capacity of Lu-177 to meet general demand.
Based on available project data, the specific IP and licensing terms for the Ytterbium recycling process are not mentioned.
The project runs from 2024-10-01 to 2029-03-31, including an observational clinical trial with 150 patients.
The project develops upgrades for 7T systems and a CEST-based approach that works with standard 1.5T MRI systems using a contrast agent.
The consortium is highly commercially oriented with a 47% industry ratio, comprising 7 industrial partners (including major players like Philips and Bracco) and 3 SMEs. This balance, combined with 8 academic and research institutions across 5 countries, suggests a strong pipeline from lab validation to industrial manufacturing and clinical deployment.
Contact the Universitaire Medisch Centrum Utrecht
Contact us to connect with the ILLUMINATE consortium for licensing MeMRI technology.
